Clinical Trials Logo

Malignant Head and Neck Neoplasm clinical trials

View clinical trials related to Malignant Head and Neck Neoplasm.

Filter by:

NCT ID: NCT02960308 Completed - Clinical trials for Head and Neck Neoplasm

Whole-Neck Computed Tomography Perfusion Scan in Imaging Patients With Head and Neck Tumors

Start date: October 20, 2016
Phase:
Study type: Observational

This pilot clinical trial studies how well whole-neck computed tomography perfusion scans work in imaging patients with head and neck tumors. Diagnostic imaging procedures, such as whole-neck computed tomography perfusions scans, may provide more information about the blood supply to head and neck tumors which may help doctors plan better treatment.

NCT ID: NCT02480114 Completed - Mucositis Clinical Trials

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

Start date: July 2015
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies how well gabapentin plus standard of care work compares to standard of care without Gabapentin in preventing inflammation of the mucous membranes (mucositis) in patients with stage III-IV head and neck cancer that are undergoing primary or subsequent (adjuvant) chemoradiation therapy. Radiation therapy to the head and neck may cause a burn involving the inside of the mouth, throat, and nasal passages, resulting in pain. Gabapentin may help prevent (or minimize) pain associated with radiation-induced mucositis in patients with head and neck cancer.

NCT ID: NCT01896778 Completed - Melanoma Clinical Trials

Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer

Start date: October 4, 2013
Phase: N/A
Study type: Interventional

This randomized pilot clinical trial studies body warming in improving blood flow and oxygen delivery to tumors in patients with cancer. Heating tumor cells to several degrees above normal body temperature may kill tumor cells.

NCT ID: NCT01366144 Active, not recruiting - Melanoma Clinical Trials

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Start date: June 20, 2011
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver or kidney dysfunction. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with paclitaxel and carboplatin may kill more tumor cells.

NCT ID: NCT01365169 Recruiting - Clinical trials for Pancreatic Adenocarcinoma

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

Start date: May 25, 2011
Phase: N/A
Study type: Interventional

The main goal of this phase of the study is to determine if objectively assessed Physical Activity (PA) levels in advanced-cancer patients are associated with health care provider (HCP)-assessed ECOG performance status and overall survival. The purpose is to advance the evidence-base for incorporating objective assessment of Physical Activity (PA) in the context of performance status assessment in advanced cancer patients.